The test can offer reference intervals for paediatric and pregnant patient populations. Credit: Fernando Zhiminaicela / Pixabay.

Ortho Clinical Diagnostics has received CE Mark for its VITROS Immunodiagnostic Products TSH3 (thyroid-stimulating hormone) Reagent Pack and Calibrator to assess thyroid and / or pituitary gland function.

Expected to be commercially available from December, the VITROS TSH3 assay runs on the VITROS XT 7600 and VITROS 5600 integrated systems and can also offer reference intervals for paediatric and pregnant patient populations.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It helps healthcare teams to diagnose and monitor patients’ thyroid and / or pituitary function during the phases of development, which cause fluctuation in thyroid hormone levels.

Additionally, the assay runs on the VITROS 3600 and VITROS ECi/ECiQ Immunodiagnostic Systems and Vitros Automation Solutions.

A third-generation TSH assay with improved accuracy, VITROS TSH3 has 24-minute turnaround time, uses sample volume of 50μL, and delivers longer, 40-day calibration stability compared to the current VITROS TSH assay.

Ortho Clinical Diagnostics clinical labs business unit head Ajoy Mahtab said: “Labs can rely on Ortho’s TSH3 test when speed, accuracy, and reliability count, like in an acute case of ‘thyroid storm’ that is life-threatening, or monitoring treatment over time.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Driven by Ortho’s belief that Because Every Test is a Life, Ortho is committed to providing labs with solutions to yield faster, more accurate, more reliable results so healthcare teams can make the most appropriate clinical decisions for their patients.”

The assay uses an Ortho VITROS MicroWell Assay Design that is not prone to biotin interference like the company’s VITROS Anti-SARS-CoV-2 Total and IgG tests, VITROS B•R•A•H•M•S PCT (Procalcitonin) assay, and VITROS High Sensitivity Troponin I Assay.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact